The panel looks ahead to the future of bladder cancer treatment, discussing how therapies may evolve beyond current EV-pembrolizumab–based strategies. The group highlights emerging approaches including dual ADC combinations, neoantigen vaccines, and biomarker-guided treatment selection, while emphasizing the potential for improved personalization of care. They also discuss the possibility that better biomarkers could identify patients suitable for bladder preservation, helping match the right therapy to the right patient. Ultimately, the conversation reflects optimism that ongoing research will lead to higher cure rates and more individualized treatment strategies.
Contributors:
Dr. Petros Grivas is a medical oncologist and professor at the University of Washington and Fred Hutchinson Cancer Center in Seattle.
Dr. Bradley McGregor is a medical oncologist at Dana-Farber in Boston.
Dr. Ashish Kamat is a urologic oncologist at MD Anderson in Houston, Texas and president of The International Bladder Cancer Group.
Dr. Sia Daneshmand is a professor of urology and oncology at the University of Southern California, Norris Comprehensive Cancer Center.
Dr. Matthew Galsky is a medical oncologist at the Icahn School of Medicine at Mount Sinai.
Dr. Guru Sonpavde is a medical oncologist and the Phase 1 new drug development program Director at the AdventHealth Cancer Institute in Orlando, Florida.